Latest Insider Transactions at Checkpoint Therapeutics, Inc. (CKPT)
This section provides a real-time view of insider transactions for Checkpoint Therapeutics, Inc. (CKPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Checkpoint Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Checkpoint Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 30
2025
|
Fortress Biotech, Inc. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,122,249
-100.0%
|
$24,488,996
$4.1 P/Share
|
|
May 30
2025
|
Barry M Salzman Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
147,007
-100.0%
|
-
|
|
May 30
2025
|
Michael S Weiss Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
187,007
-100.0%
|
-
|
|
May 30
2025
|
Christian Bechon Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
141,718
-100.0%
|
-
|
|
May 30
2025
|
William Garrett Gray Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,446,322
-100.0%
|
-
|
|
May 30
2025
|
Neil Herskowitz Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
147,007
-100.0%
|
-
|
|
May 30
2025
|
James F Oliviero Iii CEO, President and Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,759,929
-100.0%
|
-
|
|
May 30
2025
|
Lindsay A Md Rosenwald Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
207,007
-100.0%
|
-
|
|
May 30
2025
|
Sharma Amit Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
94,246
-100.0%
|
-
|
|
May 29
2025
|
Fortress Biotech, Inc. |
SELL
Open market or private sale
|
Direct |
100,000
-1.61%
|
$100,000
$1.29 P/Share
|
|
May 29
2025
|
Michael S Weiss Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+21.1%
|
$50,000
$1.29 P/Share
|
|
May 29
2025
|
Lindsay A Md Rosenwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+19.45%
|
$50,000
$1.29 P/Share
|
|
May 28
2025
|
Barry M Salzman Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,195
+7.66%
|
-
|
|
May 28
2025
|
Michael S Weiss Director |
BUY
Grant, award, or other acquisition
|
Indirect |
12,195
+8.17%
|
-
|
|
May 28
2025
|
Christian Bechon Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,195
+7.92%
|
-
|
|
May 28
2025
|
Neil Herskowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,195
+7.66%
|
-
|
|
May 28
2025
|
Lindsay A Md Rosenwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,195
+7.21%
|
-
|
|
May 28
2025
|
Sharma Amit Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,195
+11.46%
|
-
|
|
Apr 02
2025
|
James F Oliviero Iii CEO, President and Director |
SELL
Open market or private sale
|
Direct |
15,090
-0.4%
|
$60,360
$4.04 P/Share
|
|
Apr 01
2025
|
William Garrett Gray Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,322
-0.84%
|
$49,288
$4.05 P/Share
|
|
Feb 26
2025
|
Fortress Biotech, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
18,500
+0.3%
|
-
|
|
Feb 10
2025
|
James F Oliviero Iii CEO, President and Director |
SELL
Open market or private sale
|
Direct |
10,331
-0.27%
|
$30,993
$3.15 P/Share
|
|
Feb 07
2025
|
James F Oliviero Iii CEO, President and Director |
SELL
Open market or private sale
|
Direct |
9,233
-0.24%
|
$27,699
$3.41 P/Share
|
|
Feb 06
2025
|
William Garrett Gray Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
74,110
-4.84%
|
$222,330
$3.67 P/Share
|
|
Jan 30
2025
|
James F Oliviero Iii CEO, President and Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,500,000
+28.33%
|
-
|
|
Jan 30
2025
|
William Garrett Gray Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+24.6%
|
-
|
|
Jan 01
2025
|
Fortress Biotech, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
2,386,808
+27.78%
|
-
|
|
Dec 31
2024
|
Fortress Biotech, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
81,407
+2.09%
|
-
|
|
Dec 20
2024
|
James F Oliviero Iii CEO, President and Director |
SELL
Bona fide gift
|
Direct |
900,000
-28.17%
|
-
|
|
Dec 19
2024
|
James F Oliviero Iii CEO, President and Director |
SELL
Open market or private sale
|
Direct |
220,230
-6.45%
|
$660,690
$3.38 P/Share
|
|
Dec 18
2024
|
William Garrett Gray Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
268,432
-20.63%
|
$1,073,728
$4.01 P/Share
|
|
Dec 18
2024
|
James F Oliviero Iii CEO, President and Director |
SELL
Open market or private sale
|
Direct |
602,167
-14.99%
|
$1,806,501
$3.87 P/Share
|
|
Dec 13
2024
|
Neil Herskowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,638
+11.57%
|
-
|
|
Dec 13
2024
|
Christian Bechon Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,994
+10.38%
|
-
|
|
Dec 13
2024
|
William Garrett Gray Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
629,000
+32.59%
|
-
|
|
Dec 13
2024
|
James F Oliviero Iii CEO, President and Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,077,700
+34.09%
|
-
|
|
Dec 13
2024
|
Lindsay A Md Rosenwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,638
+8.03%
|
-
|
|
Dec 13
2024
|
Barry M Salzman Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,638
+11.57%
|
-
|
|
Dec 13
2024
|
Michael S Weiss Director |
BUY
Grant, award, or other acquisition
|
Indirect |
12,638
+9.19%
|
-
|
|
Sep 27
2024
|
Fortress Biotech, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
146,341
+3.77%
|
-
|
|
Jun 26
2024
|
William Garrett Gray Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,038
-1.9%
|
$26,076
$2.06 P/Share
|
|
Jun 26
2024
|
James F Oliviero Iii CEO, President and Director |
SELL
Bona fide gift
|
Direct |
37,890
-1.92%
|
-
|
|
Jun 26
2024
|
James F Oliviero Iii CEO, President and Director |
SELL
Open market or private sale
|
Direct |
24,610
-1.23%
|
$49,220
$2.05 P/Share
|
|
May 24
2024
|
James F Oliviero Iii CEO, President and Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,660,000
+45.33%
|
-
|
|
May 24
2024
|
William Garrett Gray Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
540,000
+44.07%
|
-
|
|
May 14
2024
|
Sharma Amit Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,051
+28.09%
|
-
|
|
May 14
2024
|
Michael S Weiss Director |
BUY
Grant, award, or other acquisition
|
Indirect |
82,051
+32.42%
|
-
|
|
May 14
2024
|
Christian Bechon Director |
BUY
Grant, award, or other acquisition
|
Direct |
82,051
+31.79%
|
-
|
|
May 14
2024
|
Neil Herskowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
82,051
+31.11%
|
-
|
|
May 14
2024
|
Lindsay A Md Rosenwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
82,051
+27.75%
|
-
|